Loading…
Chinese pharmaceutical group making generic and biologic drugs plus in-vitro diagnostic reagents.
Chinese pharmaceutical group making generic and biologic drugs plus in-vitro diagnostic reagents.
Sells medicines and diagnostic kits mainly in China, where hospital purchasing rules press prices on older generics and test kits depend on lab volume. This is the Hong Kong share class of the same group as 000513.SZ, controlled by Joincare Pharmaceutical, a listed Chinese drug group.
In one line: A diversified Chinese generics + diagnostics maker.
Moat: narrow (scale, regulatory licence). Broad approved-product portfolio across drugs and diagnostics gives scale advantages.
Headquarters: Zhuhai, China · Founded: 1985 · Employees: 8,878
Size Livzon Pharmaceutical (1513.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.69B, the 306th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$24.58 on 6 Nov 2026.
Performance Over six months the shares fell 11.2%, against +3.9% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue fell 9.6% over the last twelve months (peer median +8.7%); the operating margin is 19.3% (peer median 13.9%).
Valuation It trades at 11.3× forward earnings against a peer median of 22.1× (3rd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.4 points above its cost of capital (6.9% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$11.6B | HK$12.9B | HK$12.7B | HK$13.6B | HK$14.6B |
| Revenue growth | — | +2% | -7% | -7% | — |
| Gross profit | HK$7.48B | HK$8.28B | HK$8.07B | HK$8.17B | HK$9.01B |
| EBITDA | n/a | HK$3.45B | HK$3.44B | HK$3.08B | HK$3.02B |
| Net income | HK$1.77B | HK$2.19B | HK$2.23B | HK$2.16B | HK$2.22B |
| Free cash flow | HK$3.19B | HK$2.83B | HK$2.63B | HK$2.84B | HK$2.28B |
| Capital expenditure | HK$476M | HK$623M | HK$618M | HK$907M | HK$1.09B |
| Total debt | HK$4.92B | HK$4.28B | HK$5.27B | HK$5.54B | HK$5.19B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Livzon Pharmaceutical 1513.HK | $3.69B | -11% | -10% | 19% | 11.3× | -7.7% |
| China Resources Pharmaceutical 3320.HK | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% |
| Simcere Pharmaceutical 2096.HK | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% |
| Sinopharm 1099.HK | $6.83B | -4% | +3% | 3% | 6.3× | -8.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1513.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.1% | +5.2% | 5th highest of 21 |
| 6-month return | -11.2% | +3.9% | 5th lowest of 20 |
| Distance from 52-week high | -25.9% | -24.8% | 10th lowest of 21 |
| Revenue growth (TTM) | -9.6% | +8.7% | 3rd lowest of 19 |
| Operating margin | 19.3% | 13.9% | 5th highest of 17 |
| Forward P/E | 11.3× | 22.1× | 3rd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -7.7% | 3.9% | least demanding of 15 |
| Growth delivered (Del g) | +2.0% | +11.3% | 2nd lowest of 15 |
| Hurdle (Req g minus delivered) | -9.6 pp | -11.9 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | +9.4 pp | +4.3 pp | 6th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 11.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | n/a | 31.9% | +159.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 159.9× | n/a | n/a |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |